---
title: "Pharvaris (PHVS) Receives a Buy from H.C. Wainwright"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286441385.md"
description: "H.C. Wainwright's Patrick Trucchio has reiterated a Buy rating on Pharvaris (PHVS) with a price target of $60.00. Trucchio, who covers the Healthcare sector, has an average return of 27.8% and a 52.26% success rate on his stock recommendations. Additionally, Jonathan Wolleben from Citizens JMP also issued a Buy rating for Pharvaris recently, while Bank of America Securities maintained a Hold rating on the stock."
datetime: "2026-05-14T15:37:45.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286441385.md)
  - [en](https://longbridge.com/en/news/286441385.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286441385.md)
---

# Pharvaris (PHVS) Receives a Buy from H.C. Wainwright

In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Pharvaris, with a price target of $60.00.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Trucchio covers the Healthcare sector, focusing on stocks such as Atai Beckley N.V., Definium Therapeutics, and Alnylam Pharma. According to TipRanks, Trucchio has an average return of 27.8% and a 52.26% success rate on recommended stocks.

In addition to H.C. Wainwright, Pharvaris also received a Buy from Citizens JMP’s Jonathan Wolleben in a report issued yesterday. However, today, Bank of America Securities maintained a Hold rating on Pharvaris (NASDAQ: PHVS).

### Related Stocks

- [PHVS.US](https://longbridge.com/en/quote/PHVS.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [ATAI.US](https://longbridge.com/en/quote/ATAI.US.md)
- [DFTX.US](https://longbridge.com/en/quote/DFTX.US.md)
- [ALNY.US](https://longbridge.com/en/quote/ALNY.US.md)
- [CFG.US](https://longbridge.com/en/quote/CFG.US.md)
- [BAC.US](https://longbridge.com/en/quote/BAC.US.md)
- [CFG-I.US](https://longbridge.com/en/quote/CFG-I.US.md)
- [CFG-E.US](https://longbridge.com/en/quote/CFG-E.US.md)
- [CFG-H.US](https://longbridge.com/en/quote/CFG-H.US.md)
- [BAC-Q.US](https://longbridge.com/en/quote/BAC-Q.US.md)
- [BML-L.US](https://longbridge.com/en/quote/BML-L.US.md)
- [BAC-L.US](https://longbridge.com/en/quote/BAC-L.US.md)
- [BAC-K.US](https://longbridge.com/en/quote/BAC-K.US.md)
- [BML-H.US](https://longbridge.com/en/quote/BML-H.US.md)
- [BAC-N.US](https://longbridge.com/en/quote/BAC-N.US.md)
- [BAC-E.US](https://longbridge.com/en/quote/BAC-E.US.md)
- [MER-K.US](https://longbridge.com/en/quote/MER-K.US.md)
- [BAC-O.US](https://longbridge.com/en/quote/BAC-O.US.md)
- [BML-G.US](https://longbridge.com/en/quote/BML-G.US.md)
- [BAC-M.US](https://longbridge.com/en/quote/BAC-M.US.md)
- [BAC-B.US](https://longbridge.com/en/quote/BAC-B.US.md)
- [BML-J.US](https://longbridge.com/en/quote/BML-J.US.md)
- [BAC-S.US](https://longbridge.com/en/quote/BAC-S.US.md)
- [BAC-P.US](https://longbridge.com/en/quote/BAC-P.US.md)
- [8648.JP](https://longbridge.com/en/quote/8648.JP.md)

## Related News & Research

- [LifeSci Capital Sticks to Their Buy Rating for Tenax Therapeutics (TENX)](https://longbridge.com/en/news/286648286.md)
- [Roth MKM Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)](https://longbridge.com/en/news/286497683.md)
- [Acrivon Therapeutics, Inc. (ACRV) Receives a Buy from Oppenheimer](https://longbridge.com/en/news/286428001.md)
- [14:05 ETLupin Receives Tentative Approval from U.S. FDA for Revefenacin Inhalation Solution](https://longbridge.com/en/news/286805922.md)
- [Relay's treatment shown to shrink vascular malformations in mid-stage trial](https://longbridge.com/en/news/286890329.md)